[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CEN Biotech\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100621427","knee-osteoarthritis-and-thermal-spa-treatment-100621427",false,"NCT07370480","Knee Osteoarthritis and Thermal Spa Treatment","Evaluation of the Effectiveness of the Enghien-les-Bains Thermal Spa Treatment in the Rheumatology Indication in Patients With Knee Osteoarthritis. Indirect Comparison Study.","ENERGIE","Inclusion Criteria:\n\n* Knee osteoarthritis with Kellgren and Lawrence stage 2 to 4 evidenced by a knee X-ray examination in the past 3 years.\n* 100-normalized score of the WOMAC physical function subscale greater than or equal to 30.\n* Signed inform consent.\n* With health insurance affiliation.\n\nExclusion Criteria:\n\n* Presented with balneotherapy contraindication or to certain adjuvant treatment techniques (balneation, hydrotherapy jets, massage): chronic infectious pathology, active cancer, decompensated cardiac, hepatic or renal insufficiency, \"open\" leg ulcer, immune deficiency, phlebitis, erysipelas or history of erysipelas, active thrombosis, behavioral disorders, etc.\n* Presented with chronic pain for reasons other than osteoarthritis: chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, lupus, psoriatic arthritis) or fibromyalgia.\n* Patient scheduled for knee osteoarthrosis-related surgery within the next 7 months.\n* Having had spa treatment in the past 6 months whatever the indication or intra-articular corticosteroid injection within the previous 90 days or hyaluronic acid infiltration or other viscosupplementation or platelet-rich plasma (PRP) injection within the previous 6 months.\n* Having planned a spa treatment in another indication between inclusion and final visit.\n* Residing more than 30 kilometers from Enghien-les-Bains at the time of spa treatment.\n* Women of childbearing potential who are not using effective contraception (estrogen\u002Fprogestin or progestin-only oral, vaginal, transdermal, injectable or subcutaneous) or who plan to discontinue contraception within the next 7 months.\n* Likely to be unable to comply with protocol or to attend visits, particularly in view of the duration of the research, or unable to read or understand French.\n* Regulatory reason (guardianship or already enrolled in a clinical trial).\n* Already included in a clinical trial or in the exclusion period of a clinical trial.","ALL","50 Years","80 Years",{"count":21,"type":22},76,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this interventional study is to evaluate the effectiveness at 6 months of the Enghien-les-Bains thermal spa treatment on functional disability and pain, assessed by the Minimal Clinically Important Improvement (MCII), in patients with knee osteoarthritis.\n\nThe study is conducted in patients aged 50 to 80 years with knee osteoarthritis (Kellgren-Lawrence grade 2 to 4) and a baseline functional impairment defined by a normalized WOMAC function score ≥ 30.\n\nThe main questions it aims to answer are:\n\n* Does the Enghien-les-Bains thermal spa treatment result in a clinically meaningful improvement in pain and functional disability at 6 months in patients with knee osteoarthritis?\n* Is the effectiveness of the Enghien-les-Bains thermal spa treatment superior to standard care, as assessed through an indirect comparison with an external control group from the ANGELLO randomized controlled trial (NCT0581943)? Patients receiving the Enghien-les-Bains thermal spa treatment are compared to the external control group of the ANGELLO randomized controlled trial (Saint-Jean-d'Angély), composed of non-spa-treated patients receiving standard care, to assess differences in pain and functional disability outcomes at 6 months.\n\nPatients of the study:\n\n* Undergo a standardized thermal spa treatment at Enghien-les-Bains.\n* Continue usual medical care for knee osteoarthritis.\n* Complete questionnaires and clinical assessments at baseline and at 6 months.",[28],"Knee Osteoarthritis",[30,31,32,33],"spa therapy","thermal treatment","balneotherapy","Rheumatology","RECRUITING","2026-01-29",{"date":37,"type":38},"2026-01-30","ACTUAL",{"date":40,"type":38},"2026-01-27",{"date":42,"type":22},"2027-12-31",{"name":44,"class":45},"CEN Biotech","INDUSTRY",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100615674","urgo-filmocream-eczema--dermocorticoids-in-atopic-dermatitis-100615674","NCT07295678","URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis","Open-label Clinical Investigation to Evaluate the Performance and Safety of Medical Device \"Urgo Filmocream Eczema\" in Association With Dermocorticoids on Atopic Dermatitis Lesions","GERONIMO","Inclusion Criteria:\n\n1. Male or female subject.\n2. Aged 18 or more.\n3. With mild to moderate atopic dermatitis based on the Investigator's Global Assessment for Atopic Dermatitis (IGA-AD).\n4. Presence of two comparable atopic dermatitis lesions requiring treatment with topical corticosteroids, located at anatomically distant sites.\n5. Having given her\u002Fhis informed, written consent,\n6. Cooperative, fully informed of the treatment procedures, and aware of the importance and schedule of follow-up visits, ensuring expected full adherence to the study protocol.\n7. Psychologically capable of understanding the study information and providing informed consent.\n8. Affiliated to a health social security system.\n9. Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after the study end and must have a negative urine pregnancy test before the first treatment.\n\nExclusion Criteria:\n\n1. Subject currently participating in another clinical study that may interfere with the assessments of the present study, according to the investigator's judgment.\n2. Subject unable to understand the information provided - including study procedures - due to linguistic or psychiatric reasons, and therefore unable to give written informed consent or to complete the study diary as required.\n3. Subject who, in the investigator's judgment, is unlikely to comply with study-related constraints and requirements.\n4. Subject who has forfeited his\u002Fher freedom by administrative or legal decision, or who is under legal guardianship.\n5. Female subject of childbearing potential who is pregnant, breastfeeding, or planning to become pregnant during the study.\n6. Subject with a known contraindication to topical corticosteroids, such as hypersensitivity to desonide, betamethasone, or any component of the prescribed corticosteroid formulations.\n7. Subject with broken or ulcerated skin, acne, rosacea (including perioral dermatitis), any untreated or active skin infection (viral, bacterial, or fungal), or skin thinning at the application sites.\n8. Subject with a skin disease, abnormality, or dermatological condition in the study area that may interfere with study assessments.\n9. Subject with acute, chronic, or progressive disease, or relevant medical history, considered by the investigator to be hazardous for the subject, incompatible with the study, or likely to interfere with study assessments.\n10. Any systemic treatment, including oral corticosteroids, that is incompatible with the study or likely to interfere with study assessments according to the investigator, administered in the weeks prior to the inclusion visit, ongoing, or planned to start during the study.\n11. Any topical treatment on the tested area that is incompatible with the study or likely to interfere with study assessments according to the investigator, administered in the weeks prior to the inclusion visit.","18 Years",{"count":57,"type":22},44,[25],"The goal of this clinical study is to determine whether URGO FilmoCream Eczema is effective as a non-steroidal treatment to relieve symptoms of atopic dermatitis. It also aims to evaluate the cream's ability to moisturize, soothe irritation, protect the skin, and promote healing of eczema lesions. The main questions the study seeks to answer are:\n\n1. Does URGO FilmoCream Eczema improve symptom relief of atopic dermatitis when used alongside standard topical corticosteroid treatment?\n2. How do eczema lesions treated with topical corticosteroids alone progress and heal compared to those treated with topical corticosteroids plus URGO FilmoCream Eczema? To investigate this, patients with at least two similar eczema lesions are enrolled. One lesion is treated with topical corticosteroids alone, while the other is treated with topical corticosteroids plus URGO FilmoCream Eczema.\n\nThe progression of both lesions is monitored throughout treatment, until healing, and for 28 days after the last application of topical corticosteroids.",[61],"Atopic Dermatitis",[63,64,65],"eczema lesions","adjuvant treatment to dermocorticoids","URGO FilmoCream Eczema","NOT_YET_RECRUITING","2025-12-19",{"date":69,"type":38},"2025-12-26",{"date":71,"type":22},"2026-01-05",{"date":73,"type":22},"2026-12-31",{"name":44,"class":45},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":101},"100563577","knee-osteoarthritis-and-spa-therapy-100563577","NCT06617975","Knee Osteoarthritis and Spa Therapy","Evaluation of the Effectiveness of the Spa Therapy Program for Rheumatology at Santenay in Patients With Knee Osteoarthritis","SANTIAGO","Inclusion Criteria:\n\n* Knee osteoarthritis with Kellgren and Lawrence stage 2 to 4 evidenced by a knee X-ray examination in the past 3 years.\n* 100-normalized score of the WOMAC physical function subscale greater than or equal to 30.\n* Accepting a prescription for a balneotherapy program in the Rheumatology at Santenay spa as part of the management of their knee osteoarthritis issued by the investigator.\n* Signed inform consent.\n* With health insurance affiliation.\n\nExclusion Criteria:\n\n* Presented with balneotherapy contraindication or to certain adjuvant treatment techniques (balneation, hydrotherapy jets, massage): chronic infectious pathology, active cancer, decompensated cardiac, hepatic or renal insufficiency, \"open\" leg ulcer, immune deficiency, phlebitis, erysipelas or history of erysipelas, active thrombosis, behavioral disorders, etc.\n* Presented with chronic pain for reasons other than osteoarthritis: chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, lupus, psoriatic arthritis) or fibromyalgia.\n* Having had spa treatment in the past 6 months whatever the indication or intra-articular corticosteroid injection within the previous 90 days or hyaluronic acid infiltration within the previous 6 months.\n* Having planned a spa treatment in another indication between inclusion and final visit.\n* Patient scheduled for knee osteoarthrosis-related surgery within the next 7 months.\n* Residing more than 30 kilometers from Santenay at the time of spa treatment. Women of childbearing potential who are not using effective contraception (estrogen\u002Fprogestin or progestin-only oral, vaginal, transdermal, injectable or subcutaneous) or who plan to discontinue contraception within the next 7 months.\n* Likely to be unable to comply with protocol or to attend visits, particularly in view of the duration of the research, or unable to read or understand French.\n* Regulatory reason (guardianship or already enrolled in a clinical trial).\n* Already included in a clinical trial or in the exclusion period of a clinical trial.",{"count":84,"type":22},80,[25],"The aim of this clinical trial is to assess the efficacy of the 18-day balneotherapy program (therapeutic indication: Rheumatology) in terms of functional incapacity and the disorders (pain, joint stiffness) induced by osteoarthritis of the knee, and thus improves patients\\' quality of life, in patients presented with knee osteoarthritis.\n\nThe French National Academy of Medicine encourages the re-use of RCT data when available. In this context, the current study is designed as a single-arm prospective study with external comparison using the propensity score. The Control group consists of the patients which were allocated to the Control group of reference randomized clinical trial (RCT) \"ANGELLO Study\" (NCT05819437). These patients received standard care for knee osteoarthritis, i.e., pain management and exercise recommendations.\n\nAll patients enrolled in the current study benefit of 18-day balneotherapy program (therapeutic indication: Rheumatology) with Mineral Water of Santenay (Burgundy, France), and examination with a practitioner at enrollment and 6 months after the beginning of spa treatment.",[28,88],"Knee Osteoarthritis (OA)",[90,91,33,92,93],"Balneotherapy","Spa therapy","Knee osteoarthritis","WOMAC","2025-08-04",{"date":96,"type":38},"2025-08-07",{"date":98,"type":38},"2024-10-14",{"date":73,"type":22},{"name":44,"class":45},1,""]